INNT
TOTAL INVALIDATION PROCESSED BY THE IB
19/03/2026
Voltar para busca
Dado oficial do USPTO
TOLERO PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TOLERO PHARMACEUTICALS
ST13
US500000079212382Classe
5, 44
Pedido
79212382
Registro
5505386
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
20/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 44
Data de depósito
22/03/2017
Data de registro
03/07/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/01/2025
Última transação
20/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Osaka 541-0045, JP
Examinador
FOSDICK, GEOFFREY A
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Sumitomo Dainippon Pharma Co., Ltd.
Representantes
Howard N. Aronson Lackenbach Siegel LLP
Classificação técnica
Classes Nice
Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsanti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous systemdiseases of the brainmovementocular motility and spinal cord diseasesencephalitisepilepsyAlzheimer'scerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous systemamyotrophic lateral sclerosisnumbnesslightheadednessdysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital systemurological diseasesinfertilitysexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the cardiovascular system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the endocrine systemgrowth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic systemdiabeteshypoglycemiagoutosteoarthritismuscular dystrophyanemiabulimia nervosaanorexiaobesity and hypothyroidism; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the renal system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the gastroenterological system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the ophthalmologic system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the dermatologic systemdermatitiseczemapsoriasisskin pigmentation diseases and sexually transmitted diseases; pharmaceutical preparations for the prevention and treatment of hematologic and oncologic disorders and diseases; pharmaceutical preparations for the prevention and treatment of psychiatric disorders and diseasesanxiety disordersmood disordersschizophreniacognitive and bipolar disordersepilepsyParkinson's diseaseAlzheimer's diseasecerebral palsymultiple sclerosis and seizures; pharmaceutical preparations for the prevention and treatment of allergic disorders and diseases and disorders and diseases of the immune systemautoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of connective tissue and jointsconnective tissue diseasesbone diseasesspinal diseasesback painfractures and cartilage injuries; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for use in chemotherapy
Classe 44
Providing medical information
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
28/02/2026
INPC
INVALIDATION PROCESSED
28/02/2026
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
17/09/2025
C71T
CANCELLED SECTION 71
17/01/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/07/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/10/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/10/2018
FIMP
FINAL DISPOSITION PROCESSED
04/10/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/10/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
03/07/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/04/2018
PUBO
PUBLISHED FOR OPPOSITION
17/04/2018
GPNX
NOTIFICATION PROCESSED BY IB
13/04/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/03/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/03/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
28/03/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/03/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/03/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/03/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/03/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/12/2017
GNRT
NON-FINAL ACTION E-MAILED
22/12/2017
CNRT
NON-FINAL ACTION WRITTEN
22/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/12/2017
ALIE
ASSIGNED TO LIE
15/12/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/12/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/11/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/11/2017
RFNT
REFUSAL PROCESSED BY IB
12/08/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/07/2017
RFRR
REFUSAL PROCESSED BY MPU
27/07/2017
MAFR
APPLICATION FILING RECEIPT MAILED
25/07/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/07/2017
CNRT
NON-FINAL ACTION WRITTEN
20/07/2017
DOCK
ASSIGNED TO EXAMINER
19/07/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/07/2017
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
14/07/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/07/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TOLERO PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.